Switzerland: Linnea obtains license to produce and export high-THC APIs

A Linnea SA obtained the narcotics license from Swissmedic, the Swiss equivalent of Infarmed IP, making it one of the first companies in Switzerland to be authorized to produce and export active pharmaceutical ingredients (APIs) with high THC content. This license allows Linnea to export its standardized and innovative high-THC APIs to any location in the world where it is legal to import them.

A Linnea Cannabinoids, a division of Linnea SA, aims to manufacture the highest quality pharmaceutical cannabinoid ingredients and drive research and innovation within the industry. The company has been providing high quality botanical ingredients for use in the pharmaceutical, cosmetic and dietary supplement industries for over 40 years. However, in 2016, Linnea decided to enter the cannabis and cannabinoid industry, with the aim of expanding its portfolio and bringing its cannabinoid pharmaceutical products to a wider global audience.

Susanne Caspar, CEO of Linnea SA, expressed her excitement about the recent development and the opportunities it represents for the company. In Press release, stated: “We are honored to have been granted a narcotics license in Switzerland. This opens up many new commercial possibilities for Linnea Cannabinoids and our customers. High quality cannabinoid ingredients are essential for producing the pharmaceuticals that patients need and we look forward to contributing our expertise to this effort. We look forward to the opportunities this will provide us in creating new partnerships and continuing to innovate in the industry.”